Regulus Therapeutics is a biopharmaceutical company at the forefront of discovering and developing innovative medicines that target microRNAs. Leveraging a mature therapeutic platform that is based on technology developed over 20 years, the company is advancing microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases. The company has strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi, as well as a research collaboration with Biogen Idec. For more information, visit the company’s Web site at www.regulusrx.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: